CAS 698387-09-6

Neratinib

Description:

Neratinib is a small molecule tyrosine kinase inhibitor primarily used in the treatment of certain types of breast cancer, particularly those that are HER2-positive. It functions by irreversibly binding to the HER2 receptor, thereby inhibiting its signaling pathways that promote tumor growth and proliferation. Neratinib is characterized by its chemical formula, which includes a complex structure featuring a quinazoline core. It is typically administered orally and has a relatively long half-life, allowing for once-daily dosing. The substance is known for its potential side effects, which may include diarrhea, nausea, and fatigue, among others. Neratinib has been studied in various clinical trials and has received regulatory approval for use in specific patient populations, highlighting its significance in targeted cancer therapy. Its mechanism of action and efficacy make it a valuable option in the therapeutic landscape for HER2-positive breast cancer, particularly in patients who have previously been treated with trastuzumab.

Formula: C₃₀H₂₉ClN₆O₃

InChI: InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+

InChI key: InChIKey=JWNPDZNEKVCWMY-VQHVLOKHSA-N

SMILES: N(C=1C2=C(C=C(OCC)C(NC(/C=C/CN(C)C)=O)=C2)N=CC1C#N)C3=CC(Cl)=C(OCC4=CC=CC=N4)C=C3

Synonyms:

• (2E)-N-(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide
• (2E)-N-[4-[[3-Chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide
• (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
• (E)-N-[4-[3-Chloro-4-[(2-pyridinyl)methoxy]anilino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide
• (E)-N-[4-[[3-Chloro-4-((pyridin-2-yl)methoxy)phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)-2-butenamide
• 2-Butenamide, N-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-, (2E)-
• Hki-272
• Neratinib

Neratinib

CAS: 698387-09-6

Formula: C₃₀H₂₉ClN₆O₃

Purity: >95.0%(T)(HPLC)

Color and Shape: White to Light yellow powder to crystal

Molecular weight: 557.05

Ref: 3B-N1062

(2E)-N-(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide

CAS: 698387-09-6

Formula: C₃₀H₂₉ClN₆O₃

Purity: 98%

Color and Shape: Solid

Molecular weight: 557.0427

Ref: IN-DA0035DM

Neratinib

CAS: 698387-09-6

Formula: C₃₀H₂₉ClN₆O₃

Purity: ≥ 98.0%

Color and Shape: White, off-white, beige or pale yellow crystalline powder

Molecular weight: 557.04

Ref: 7W-GP9212

Neratinib

CAS: 698387-09-6

Neratinib

Purity: ≥95%

Molecular weight: 557.04g/mol

Ref: 54-BUP17182

Neratinib

CAS: 698387-09-6

Formula: C₃₀H₂₉ClN₆O₃

Color and Shape: Yellow Solid

Molecular weight: 557.05

Ref: 4Z-N-088001

Neratinib

CAS: 698387-09-6

Neratinib

Formula: C₃₀H₂₉ClN₆O₃

Purity: 99.9% (Typical Value in Batch COA)

Color and Shape: pale yellow solid

Molecular weight: 557.04g/mol

Ref: 54-BIFK0031

Neratinib

CAS: 698387-09-6

Neratinib (HKI-272) (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor for HER2 and EGFR (IC50: 59/92 nM), respectively.

Formula: C₃₀H₂₉ClN₆O₃

Purity: 96.17% - 99.85%

Color and Shape: Solid

Molecular weight: 557.04

Ref: TM-T2325

Neratinib

Controlled Product

CAS: 698387-09-6

Applications An oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Antitumor agent.
References Vogel, C., et al.: J. Clin. Oncol., 20, 719 (2002), Ji, H., et al.: Cancer Cell., 9, 485 (2006), Sequist, L., et al.: Oncologist, 12, 325 (2007),

Formula: C₃₀H₂₉ClN₆O₃

Color and Shape: Neat

Molecular weight: 557.04

Ref: TR-N390090

Neratinib - Bio-X ™

CAS: 698387-09-6

Neratinib is a protein kinase inhibitor that is used in the treatment of breast cancer. This drug binds to and inhibits EGFR, HER2 and HER4. As a result of this, it prevents autophosphorylation of tyrosine residues and reduces oncogenic signalling.

Formula: C₃₀H₂₉ClN₆O₃

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 557.04 g/mol

Ref: 3D-BN164645

Neratinib bis-N-Oxide (M11)

Controlled Product

CAS: 698387-09-6

Formula: C₃₀H₂₉ClN₆O₅

Color and Shape: Neat

Molecular weight: 589.042

Ref: TR-N390180

Neratinib

CAS: 698387-09-6

Irreversible ErbB receptor tyrosine kinase inhibitor

Formula: C₃₀H₂₉ClN₆O₃

Purity: Min. 95%

Color and Shape: White Powder

Molecular weight: 557.04 g/mol

Ref: 3D-FN65101